DaVita stock soars to all-time high of $169.54 amid robust growth

Published 21/01/2025, 18:10
DaVita stock soars to all-time high of $169.54 amid robust growth

DaVita Inc . (NYSE:DVA) shares reached an all-time high this week, touching $169.54, as the company continues to demonstrate strong performance and investor confidence. With a market capitalization of $13.9 billion and a P/E ratio of 17.8, InvestingPro analysis suggests the stock is trading slightly above its Fair Value. The surge to this record price level underscores a remarkable year for the healthcare provider, with the stock witnessing an impressive 61.76% increase over the past year. This significant 1-year change reflects the company's robust operational results and strategic initiatives that have resonated well with investors, fueling the stock's upward trajectory to its highest point ever. InvestingPro data reveals the company maintains a "GREAT" overall financial health score, with analysts setting price targets ranging from $134 to $186. Discover 10+ additional exclusive insights and detailed analysis in the Pro Research Report, available with an InvestingPro subscription.

In other recent news, DaVita Inc. maintained its adjusted operating income guidance for 2024 between $1.91 billion and $2.01 billion, despite facing challenges such as hurricanes and supply issues. The company reported an adjusted operating income of $535 million and earnings per share of $2.59 for the quarter. The firm's debt management has been successful, with the nearest maturity now in 2028, and leverage is within the target range. DaVita also repurchased 2.7 million shares in the third quarter and approximately 600,000 in October 2023. The company is preparing for operational adjustments and growth opportunities, with an update expected in the Q4 earnings call. Despite hurricane impacts, DaVita anticipates a treatment growth rate of 50 to 100 basis points for the full year. Lastly, the company expects the final CMS 2025 rule to include transitioning oral-only drugs into Medicare Part B. These recent developments indicate the firm's resilience in navigating current challenges while preparing for future growth opportunities.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.